Ilke Aernout

Ilke Aernout

Auto-generated profile, based on publicly available information

Ilke Aernout

Ghent Research Group on Nanomedicines, Ghent University, Ghent, Belgium

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
RMRupert Mayer
Rupert Mayer
RVRein Verbeke
Rein Verbeke
CACaroline Asselman
Caroline Asselman
IAIlke Aernout
Ilke Aernout
AGAdillah Gul
Adillah Gul
FIFrancis Impens
Francis Impens
Listeria monocytogenesis a foodborne intracellular bacterial pathogen leading to human listeriosis. Despite a high mortality rate and increasing antibiotic resistance no clinically approved vaccine againstListeriais available. AttenuatedListeriastrains offer protection and are tested as antitumor vaccine vectors, but would benefit from a better knowledge on immunodominant vector antigens. To identify novel antigens, we screen forListeriapeptides presented on the surface of infected human cell lines by mass spectrometry-based immunopeptidomics. In between more than 15,000 human self-peptides, we detect 68Listeriaimmunopeptides from 42 different bacterial proteins, including several known antigens. Peptides presented on different cell lines are often derived from the same bacterial surface proteins, classifying these antigens as potential vaccine candidates. Encoding these highly presented antigens in lipid nanoparticle mRNA vaccine formulations results in specific CD8+ T-cell responses and induces protection in vaccination challenge experiments in mice. Our results can serve as a starting point for the development of a clinical mRNA vaccine againstListeriaand aid to improve attenuatedListeriavaccines and vectors, demonstrating the power of immunopeptidomics for next-generation bacterial vaccine development.

10 July 2023 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
JDJoke Deprez
Joke Deprez
RVRein Verbeke
Rein Verbeke
SMSofie Meulewaeter
Sofie Meulewaeter
IAIlke Aernout
Ilke Aernout
HDHeleen Dewitte
Heleen Dewitte
ILIne Lentacker
Ine Lentacker

29 July 2025 in Nature Microbiology
Verified
Journal Article
Closed access
IAIlke Aernout
Ilke Aernout
RVRein Verbeke
Rein Verbeke
FTFabien Thery
Fabien Thery
PWPatrick Willems
Patrick Willems
UEUri Elia
Uri Elia
ILIne Lentacker
Ine Lentacker

24 February 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
AGAdillah Gul
Adillah Gul
LMLaura Van Moortel
Laura Van Moortel
PWPatrick Willems
Patrick Willems
IAIlke Aernout
Ilke Aernout
LPLaura Pedró-Cos
Laura Pedró-Cos
FIFrancis Impens
Francis Impens
Mass spectrometry (MS)-based immunopeptidomics is a powerful approach for untargeted discovery of peptides presented on major histocompatibility complex (MHC) molecules, which can guide the selection of vaccine antigens and immunotherapy targets. First-generation immunopeptidomics workflows require processing of hundreds of millions of cells using lengthy, manual procedures. More recent approaches focus on increasing either sensitivity or throughput, but rarely combine both aspects. Here, we describe a semi-automated immunopeptidomics platform that combines high sensitivity with high throughput by implementing highly optimized conditions for immunoprecipitation, elution and purification of MHC class I and II peptides on a 96-well positive-pressure device. Upon analysis of 25% of the eluate from 16 million cells, our workflow identified over 13,500 MHC I and 6,000 MHC II peptides on a timsTOF SCP mass spectrometer, operating in DDA-PASEF mode. Exploring the sensitivity limits of our platform, we identified over 1,000 MHC I peptides from as few as 20,000 JY cells. Validating the platform’s performance for quantitative biological discovery, we report the identification of known and novel bacterial immunopeptides from U937 macrophages infected with Listeria monocytogenes or Bacillus Calmette-Guérin (BCG). Together, our optimized immunopeptidomics platform enables robust immunopeptide detection from lower-input samples in a high-throughput fashion, enabling its use for biological applications where sample amounts are limiting.